VIRAX BIOLABS GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.69 USD | -1.43% |
|
+1.89% | -52.74% |
| Sales 2024 * | 1.4M 1.91M | Sales 2025 * | 8.08M 11.04M | Capitalization | 1.63M 2.23M |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 1.16 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.2 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 11 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 73.2% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.43% | ||
| 1 week | +1.89% | ||
| Current month | -3.77% | ||
| 1 month | -8.00% | ||
| 3 months | -32.55% | ||
| 6 months | -72.62% | ||
| Current year | -52.74% |
1 week
0.61
0.74
1 month
0.610.90
Current year
0.611.43
1 year
0.615.45
3 years
0.61290.00
5 years
0.61290.00
10 years
0.61290.00
| Managers | Title | Age | Since |
|---|---|---|---|
James Foster
CEO | Chief Executive Officer | 37 | 12-12-31 |
Jason Davis
DFI | Director of Finance/CFO | 52 | 22-05-01 |
Mark Ternouth
CTO | Chief Tech/Sci/R&D Officer | 56 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Nelson Haight
BRD | Director/Board Member | 58 | - |
Evan Norton
BRD | Director/Board Member | 49 | - |
James Foster
CEO | Chief Executive Officer | 37 | 12-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.69 | -1.43% | 3,036 |
| 24-04-25 | 0.7 | +5.49% | 8,496 |
| 24-04-24 | 0.6636 | +0.85% | 1,895 |
| 24-04-23 | 0.658 | -6.67% | 40,051 |
| 24-04-22 | 0.705 | +4.11% | 5,284 |
Delayed Quote Nasdaq, April 26, 2024 at 04:30 pm
More quotes
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing a T-Cell Test technologies with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against global viral threats. Its product portfolio includes ViraxClear and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus. Its T-Cell testing is effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -52.74% | 1.63M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- VRAX Stock
